Standard Chartered PLC (LON:STAN – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as GBX 847.20 ($11.00) and last traded at GBX 847.20 ($11.00), with a volume of 4990964 shares traded. The stock had previously closed at GBX 836.60 ($10.86).
Analyst Upgrades and Downgrades
Several research firms recently issued reports on STAN. Berenberg Bank restated a “buy” rating and set a GBX 1,100 ($14.28) price objective on shares of Standard Chartered in a research report on Wednesday, August 21st. JPMorgan Chase & Co. raised their price target on shares of Standard Chartered from GBX 1,000 ($12.98) to GBX 1,020 ($13.24) and gave the stock an “overweight” rating in a report on Thursday, August 1st. Finally, Citigroup reiterated a “neutral” rating on shares of Standard Chartered in a report on Monday, September 2nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of GBX 979.67 ($12.72).
Get Our Latest Stock Analysis on STAN
Standard Chartered Trading Up 1.3 %
Standard Chartered Cuts Dividend
The company also recently announced a dividend, which was paid on Thursday, October 10th. Stockholders of record on Thursday, August 8th were issued a $0.09 dividend. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend was Thursday, August 8th. Standard Chartered’s payout ratio is currently 2,643.68%.
About Standard Chartered
Standard Chartered PLC, together with its subsidiaries, provides various banking products and services in Asia, Africa, the Middle East, Europe, and the Americas. The company operates in three segments: Corporate, Commercial & Institutional Banking; Consumer, Private & Business Banking; and Ventures.
Read More
- Five stocks we like better than Standard Chartered
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Health Care Stocks Explained: Why You Might Want to Invest
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- With Risk Tolerance, One Size Does Not Fit All
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Standard Chartered Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard Chartered and related companies with MarketBeat.com's FREE daily email newsletter.